Ifat Vigiser

6 Weizmann Street, 6423906
Tel Aviv, TA 64239, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis.

Circulating microRNA expression profiles as biomarkers of disease activity in multiple sclerosis.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: February 11, 2026

Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies.

Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: December 01, 2025

Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.

Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.

Journal: Journal of neurology

Published: February 15, 2025

Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study.

Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: December 18, 2024

Hyperreflective retinal foci are associated with retinal degeneration after optic neuritis in neuromyelitis optica spectrum disorders and multiple sclerosis.

Hyperreflective retinal foci are associated with retinal degeneration after optic neuritis in neuromyelitis optica spectrum disorders and multiple sclerosis.

Journal: European journal of neurology

Published: August 30, 2024

Long-term cognitive outcomes in Susac syndrome: A case series.

Long-term cognitive outcomes in Susac syndrome: A case series.

Journal: Journal of neuroimmunology

Published: February 07, 2024

Real-World experience with efgartigimod in patients with myasthenia gravis.

Real-World experience with efgartigimod in patients with myasthenia gravis.

Journal: Journal of neurology

Published: January 29, 2024

Smartphone-based gait assessment for multiple sclerosis.

Smartphone-based gait assessment for multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: September 09, 2023

Olfactory function in Susac syndrome.

Olfactory function in Susac syndrome.

Journal: Clinical neurology and neurosurgery

Published: April 14, 2023

JCV seroconversion rate during the SARS COVID-19 pandemic.

JCV seroconversion rate during the SARS COVID-19 pandemic.

Journal: Multiple sclerosis and related disorders

Published: August 31, 2022

BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.

BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.

Journal: Journal of neurology

Published: May 29, 2022

CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.

CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.

Journal: Journal of neuroimmunology

Published: April 17, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026